Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Constantijn H J, Muselaers"'
Autor:
Dagmar Grob, Bastiaan M. Privé, Constantijn H. J. Muselaers, Niven Mehra, James Nagarajah, Mark W. Konijnenberg, Steffie M. B. Peters
Publikováno v:
EJNMMI Physics, Vol 11, Iss 1, Pp 1-12 (2024)
Abstract Background Bone marrow toxicity in advanced prostate cancer patients who receive [177Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention o
Externí odkaz:
https://doaj.org/article/6dbce80e4d6b49a5afe0d91156498091
Autor:
Steffie M. B. Peters, Maaike C. T. Mink, Bastiaan M. Privé, Maarten de Bakker, Frank de Lange, Constantijn H. J. Muselaers, Niven Mehra, J. Alfred Witjes, Martin Gotthardt, James Nagarajah, Mark W. Konijnenberg
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Background Dosimetry in [177Lu]Lu-PSMA therapy is a valuable tool to assess treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol to determine the absorbed dose in organs and tumor lesions after [177
Externí odkaz:
https://doaj.org/article/3cddee000ded4238802511c9b9319d05
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Willemijn A. van Gemert, Michel de Groot, Harm Westdorp, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Abstract Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-fr
Externí odkaz:
https://doaj.org/article/d0eae2f7bc184b94b9f6863ede0c30e8
Autor:
Alfredo Distante, Laura Marandino, Riccardo Bertolo, Alexandre Ingels, Nicola Pavan, Angela Pecoraro, Michele Marchioni, Umberto Carbonara, Selcuk Erdem, Daniele Amparore, Riccardo Campi, Eduard Roussel, Anna Caliò, Zhenjie Wu, Carlotta Palumbo, Leonardo D. Borregales, Peter Mulders, Constantijn H. J. Muselaers
Publikováno v:
Diagnostics, Vol 13, Iss 13, p 2294 (2023)
Renal cell carcinoma (RCC) is characterized by its diverse histopathological features, which pose possible challenges to accurate diagnosis and prognosis. A comprehensive literature review was conducted to explore recent advancements in the field of
Externí odkaz:
https://doaj.org/article/5b8c18d640fe423cbd9db9d4679798ab
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastati
Externí odkaz:
https://doaj.org/article/05ea3477df904c7e9eba15f0eafa2c79
Autor:
Siberyn T. Nuijens, Sasja F. Mulder, Mirha Halilovic, Joost H. M. Sijm, Constantijn H. J. Muselaers
Publikováno v:
Tijdschrift voor Urologie.
SamenvattingDit case report betreft een patiënt met hematurie ten gevolge van een kiemceltumor van de linker testis, welke doorgroeide in de blaaswand. Mannen met een niet-ingedaalde testis hebben een verhoogde kans op het ontwikkelen van een testic
Autor:
Amina Banda, Bastiaan M. Privé, Youssra Allach, Maike J. M. Uijen, Steffie M. B. Peters, Cato C. Loeff, Martin Gotthardt, Constantijn H. J. Muselaers, J. Alfred Witjes, Inge M. van Oort, J. P. Michiel Sedelaar, Harm Westdorp, Niven Mehra, Fadi Khreish, Samer Ezziddin, Amir Sabet, Michael C. Kreissl, Thomas Winkens, Philipp Seifert, Marcel J. R. Janssen, Willemijn A. M. van Gemert, James Nagarajah
Publikováno v:
Cancers, 15, 1
Cancers, 15
Cancers; Volume 15; Issue 1; Pages: 297
Cancers, 15
Cancers; Volume 15; Issue 1; Pages: 297
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel treatment for patients with castration-resistant prostate cancer (CRPC). Given the mode of action, patients in an earlier disease stage, such as hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13b3270a192735ebeaacacf62523afef
Autor:
Bastiaan M. Privé, Constantijn H. J. Muselaers, Inge M. van Oort, Marcel J. R. Janssen, Steffie M. B. Peters, Willemijn A. M. van Gemert, Maike J. M. Uijen, Melline M. G. Schilham, J. P. Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O. Barentsz, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
Frontiers in Nuclear Medicine. 2
177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this pe
Autor:
Constantijn H J, Muselaers, Egbert, Oosterwijk, Desirée L, Bos, Wim J G, Oyen, Peter F A, Mulders, Otto C, Boerman
Publikováno v:
Molecular imaging. 13
A new approach in the treatment of clear cell renal carcinoma (ccRCC) is radioimmunotherapy (RIT) using anti-carbonic anhydrase IX (CAIX) antibody G250. To investigate the potential of RIT with lutetium 177 (177Lu)-labeled G250, we conducted a protei